Our pipeline

A differentiated portfolio
built for every patient journey

We are developing a portfolio of novel therapeutics targeting metabolic diseases. Substantial unmet needs persist in obesity, particularly in achieving sustained weight loss and in addressing the key underlying pathologies that impact cardiometabolic health outcomes. Alveus aims to address these critical issues, delivering meaningful improvements in patient quality of life and outcomes.

Development pipeline

A differentiated therapeutic portfolio
built for every patient journey

Alveus's pipeline is focused on next-generation metabolic therapies based on validated mechanisms; the lead asset ALV-100 is currently in Phase 2. The company's preclinical amylin pipeline consists of novel peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.

ALV-100 GIPR antagonism + GLP-1R agonism
ALV-200 AMYR3-selective peptide
ALV-300 Dual amylin-calcitonin receptor agonist (DACRA) small molecule
Fourth program Novel amylin agonist modality
Study overview

Clinical trials

Recruiting Phase 2

Preserve

Maintenance of weight loss in people previously treated with semaglutide or tirzepatide.

View study details
Active Phase 1b

ALV-100 Phase 1b

Adults with overweight or obesity, with or without type 2 diabetes.

View study details